Enormous financial damages in the domestic pharmaceutical industry due to MERS, estimated at KRW 250 billion per month

Due to the impact of patient reduction in medical institutions, influenced by the MERS spread, it is required to plan our measure to handle the situation as various damages have been generated as pharmaceutical companies not only are not able to record enough sales, but had to cancel on-going clinical trials.

The Korea Pharmaceutical Manufacturers Association (President Kyung-ho Lee), consider...